A Risk-Benefit Assessment of Metformin in Type 2 Diabetes Mellitus
Explore this paper's citation graph
Summary
Given the 4 decades of clinical experience with metformin, its antihyperglycaemic efficacy and benefits against Syndrome X, met formin offers a very favourable risk-benefit assessment when compared with the chronic morbidity and premature mortality among patients with type 2 diabetes mellitus.
- Type
- review
- Published
- 1999-06-01
- Cited by
- 213
- References
- 140
- OpenAlex
- https://openalex.org/W1964423574
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:24812036
Keywords
Medicine, Metformin, Lactic acidosis, Diabetes mellitus, Internal medicine
References
- United Kingdom Prospective Diabetes Study 24: A 6-Year, Randomized, Controlled Trial Comparing Sulfonylurea, Insulin, and Metformin Therapy in Patients with Newly Diagnosed Type 2 Diabetes That Could Not Be Controlled with Diet Therapy
- Is metformin safe enough for ageing type 2 diabetic patients?
- Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD.
- Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination.
- Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
- Drug-induced hypoglycemia. A review of 1418 cases.
- Changes in insulin receptor tyrosine kinase activity associated with metformin treatment of type 2 diabetes.
- Metformin Decreases the High Plasminogen Activator Inhibition Capacity, Plasma Insulin and Triglyceride Levels in Non-Diabetic Obese Subjects
- Management of Non-Insulin-Dependent Diabetes Mellitus
- Clinical and biochemical aspects of lactic acidosis
- Metformin kinetics in healthy subjects and in patients with diabetes mellitus.
- Similar risks of nephropathy in patients with type I or type II diabetes mellitus.
- Effect of metformin on glucose metabolism in the splanchnic bed
- Metformin improved insulin resistance in type I, insulin-dependent, diabetic patients.
- Acute Antihyperglycemic Mechanisms of Metformin in NIDDM: Evidence for Suppression of Lipid Oxidation and Hepatic Glucose Production
- Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.
- An overview of metformin in the treatment of type 2 diabetes mellitus.
- Sulphonylureas and hypoglycaemia
- Effect of metformin on glucose disposal and hyperinsulinaemia in a 14-year-old boy with acanthosis nigricans.
- The Effects of Metformin on Glycemic Control and Serum Lipids in Insulin-Treated NIDDM Patients With Suboptimal Metabolic Control
Cited by
- Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes.
- NSAIDs (Non-steroidal anti-inflammatory drugs) とメトホルミン内服により急性腎不全, 低血糖および乳酸アシドーシスを発症した先天性副腎過形成を有した2型糖尿病患者の1例
- Drug Interactions of Clinical Importance with Antihyperglycaemic Agents
- Influence of ω-3 fatty acid eicosapentaenoic acid on IGF-1 and COX-2 gene expression in granulosa cells of PCOS women
- GLP-1R, a novel receptor in platelets, and the use of liraglutide in the treatment of obesity in women with PCOS
- Hüftgelenknahe Femurfrakturen im Qualitätssicherungsmodul 17/1
- When are medication side effects due to the nocebo phenomenon
- Oral Antidiabetic Agents
- Management of Type 2 diabetes mellitus in primary care
- Empfehlungen zur Diagnostik und Behandlung von Patienten mit koronarer Herzkrankheit und Niereninsuffizienz
- Mechanisms and factors associated with gastrointestinal symptoms in patients with diabetes mellitus.
- The relationship between metformin therapy and the fasting plasma lactate in type 2 diabetes: The Fremantle Diabetes Study.
- The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Volunteers
- Safety, tolerability, and efficacy of metformin extended-release oral antidiabetic therapy in patients with type 2 diabetes: An observational trial in Asia
- Avandamet: combined metformin–rosiglitazone treatment for insulin resistance in type 2 diabetes
- SIMPLE HPLC-UV METHOD FOR DETERMINATION OF METFORMIN IN HUMAN PLASMA AND ERYTHROCYTES APPLICATION TO THERAPEUTIC DRUG MONITORING
- Optimising Therapy for Insulin-Treated Type 2 Diabetes Mellitus
- Clinical development of metformin extended-release tablets for type 2 diabetes: an overview
- Effects of rosiglitazone maleate when added to a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate renal impairment: a post hoc analysis.
- Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy.
Related papers
- Metformin-Induced Lactic Acidosis: A Case Study
- Metformin and Lactic Acidosis in Diabetic Patients
- Metformin-Induced Lactic Acidosis (MILA): Review of current diagnostic paradigm.
- Reply to: metformin – current restrictions should be alleviated
- Interpreting the Consequences of Metformin Accumulation in an Emergency Context: Impact of the Time Frame on the Blood Metformin Levels
- Metformin‐associated lactic acidosis (MALA): Moving towards a new paradigm
- Metformin-associated lactic acidosis: Current perspectives on causes and risk.
- Critical analysis of mortality in the so-called Metformin-associated lactic acidosis